INNOVANCE VWF Ac assay
Explore a solution that sets a new standard in von Willebrand factor activity determination.
The INNOVANCE® VWF Ac assay is a sensitive, reliable, and convenient test system for direct, WHO-standardized determination of von Willebrand factor (VWF) activity. It is used as an aid in the diagnosis and monitoring of congenital or acquired VWF deficiencies in patients with bleeding disorders or at risk for VWF deficiency. In addition, it can be used for monitoring VWF substitution therapy. It employs an advanced new technology, allowing the assay to mimic the way in which VWF binds to glycoprotein Ib (GPIb), the major VWF receptor protein on platelets. Because the recombinant receptor protein includes two gain-of-function mutations, the assay does not require ristocetin.
Features & Benefits
Utilizes recommended screening method
A functional assay is the preferred screening method for detecting quantitative as well as qualitative defects of von Willebrand factor.1
Direct determination of VWF activity
The INNOVANCE VWF Ac assay directly determines activity of VWF. Due to the gain-of-function mutations, VWF binding to GPIb does not require ristocetin (VWF:GPIbM)2 and is therefore less susceptible to effects of certain polymorphism variants.
Excellent correlation to the gold-standard method
The INNOVANCE VWF Ac assay shows excellent correlation with the ristocetin cofactor-based BC von Willebrand assay.
Improved VWF testing workflow
The assay employs a liquid, ready-to-use reagent that requires no stirring.
“After the positive experience we had using this assay in a study, we as caregivers in the U.S. are urgently waiting to use the INNOVANCE VWF Ac assay to diagnose our patients as we believe it supports improved von Willebrand disease (VWD) diagnosis and patient management, particularly now given the new recommendations from the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD.”
Professor of Pediatrics and Pathology, Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
Technical Specifications
Assay performance can vary from country to country as well as corresponding to the system application of the respective assay. The values listed above are provided as examples only.
INNOVANCE VWF Ac kit components*
The INNOVANCE VWF Ac assay is a turbidimetric, latex-based assay that employs a liquid, ready-to-use reagent. The assay consists of three components and can be ordered as a kit.
Reagent I
Description: Buffer with polystyrene particles coated with anti-GPIb monoclonal antibodies
* Materials required but not provided with the kit: Standard Human Plasma, Control Plasma N, Control Plasma P, Owren’s Veronal Buffer
Available on BCS XP System
Available on Siemens Healthineers and Sysmex Systems
INNOVANCE VWF Ac assay applications are available on BCS® XP Systems from Siemens Healthineers and Sysmex CS-2500 and CS-5100 Systems.
Clinical Use
Diagnostic algorithm for patients suspected of VWD1
Using functional assays in the diagnosis and monitoring of von Willebrand disease
To correctly diagnose cases involving a bleeding anamnesis or a family history of von Willebrand disease and subsequently monitor patient response to therapy, physicians require a specific test for von Willebrand factor. A functional assay is the preferred screening method for detecting quantitative as well as qualitative defects of von Willebrand factor. For more details on VWD subtypes and management, recommended lab diagnostics, and the benefits of the INNOVANCE VWF Ac assay, download the brochure.
vWF Ag assay from Siemens Healthineers
INNOVANCE VWF Ac assay and vWF Ag assay: a powerful combination
For the evaluation of von Willebrand disease, VWF activity assays can be combined with VWF antigen assays to detect and distinguish between quantitative and qualitative VWF deficiencies.1
The vWF Ag assay is an immunoturbidimetric assay that can be used on all Siemens Healthineers and Sysmex automated coagulation instruments.
Upgrade your bleeding diagnostics with a comprehensive portfolio of systems and assays
Expand to explore the bleeding portfolio from Siemens Healthineers
Did this information help you?
James PD, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. 2021 Jan 12 [published online].
Bodo I, et al. Platelet dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:1345–50.
In the U.S., platelet aggregation testing is for research use only, not for use in diagnostic procedures.
Product availability and assay performance characteristics may vary from country to country and are subject to varying regulatory requirements. Please contact your local Siemens Healthineers organization for further details.
BCS, INNOVANCE, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Sysmex is a trademark of Sysmex Corporation. All other trademarks and brands are the property of their respective owners.
